MENU
HRTS
ETF ticker: NASDAQ
PRICE
CHANGE
NET ASSETS

HRTS stock forecast, quote, news & analysis

The investment seeks to provide long-term growth of capital... Show more

Category: #Health
HRTS
Daily Signal:
Gain/Loss:
A.I.Advisor
published price charts
Interact to see
Advertisement
A.I.Advisor
a Summary for HRTS with price predictions
Jun 18, 2026

HRTS saw its Stochastic Oscillator peaks and leaves the overbought zone

The Stochastic Oscillator for HRTS moved out of overbought territory on June 17, 2026. This could be a bearish sign for the stock and investors may want to consider selling or taking a defensive position. A.I.dvisor looked at 39 similar instances where the indicator exited the overbought zone. In of the 39 cases the stock moved lower. This puts the odds of a downward move at .

Price Prediction Chart

Technical Analysis (Indicators)

Bearish Trend Analysis

The Momentum Indicator moved below the 0 level on June 18, 2026. You may want to consider selling the stock, shorting the stock, or exploring put options on HRTS as a result. In of 41 cases where the Momentum Indicator fell below 0, the stock fell further within the subsequent month. The odds of a continued downward trend are .

The Moving Average Convergence Divergence Histogram (MACD) for HRTS turned negative on June 18, 2026. This could be a sign that the stock is set to turn lower in the coming weeks. Traders may want to sell the stock or buy put options. Tickeron's A.I.dvisor looked at 29 similar instances when the indicator turned negative. In of the 29 cases the stock turned lower in the days that followed. This puts the odds of success at .

Following a 3-day decline, the stock is projected to fall further. Considering past instances where HRTS declined for three days, the price rose further in of 62 cases within the following month. The odds of a continued downward trend are .

HRTS broke above its upper Bollinger Band on May 22, 2026. This could be a sign that the stock is set to drop as the stock moves back below the upper band and toward the middle band. You may want to consider selling the stock or exploring put options.

Bullish Trend Analysis

HRTS moved above its 50-day moving average on June 04, 2026 date and that indicates a change from a downward trend to an upward trend.

The 10-day moving average for HRTS crossed bullishly above the 50-day moving average on May 22, 2026. This indicates that the trend has shifted higher and could be considered a buy signal. In of 7 past instances when the 10-day crossed above the 50-day, the stock continued to move higher over the following month. The odds of a continued upward trend are .

Following a 3-day Advance, the price is estimated to grow further. Considering data from situations where HRTS advanced for three days, in of 156 cases, the price rose further within the following month. The odds of a continued upward trend are .

The Aroon Indicator entered an Uptrend today. In of 103 cases where HRTS Aroon's Indicator entered an Uptrend, the price rose further within the following month. The odds of a continued Uptrend are .

A.I.Advisor
published Highlights

Notable companies

The most notable companies in this group are Eli Lilly & Co (NYSE:LLY), ABBVIE (NYSE:ABBV), Unitedhealth Group (NYSE:UNH), Merck & Co (NYSE:MRK), AstraZeneca PLC (NYSE:AZN), Amgen (NASDAQ:AMGN), Abbott Laboratories (NYSE:ABT), Gilead Sciences (NASDAQ:GILD), Bristol-Myers Squibb Co (NYSE:BMY), Medtronic plc (NYSE:MDT).

Industry description

The investment seeks to provide long-term growth of capital. Under normal circumstances, the fund seeks to achieve its investment objective by investing at least 80% of its net assets, which include borrowings for investment purposes, in publicly listed companies that derive at least 50% of revenues from products or services related to GLP-1 and the treatment of cardiovascular diseases and/or metabolic diseases, as defined by the Centers for Diseases Control and Preventions. The fund generally is expected to consist of more than 15 companies but not more than 100 companies. The fund is non-diversified.

Market Cap

The average market capitalization across the Tema Heart & Health ETF ETF is 96.12B. The market cap for tickers in the group ranges from 3.51M to 979.64B. LLY holds the highest valuation in this group at 979.64B. The lowest valued company is NOVN at 3.51M.

High and low price notable news

The average weekly price growth across all stocks in the Tema Heart & Health ETF ETF was 27%. For the same ETF, the average monthly price growth was 34%, and the average quarterly price growth was 91%. NTLA experienced the highest price growth at 27%, while LLY experienced the biggest fall at -5%.

Volume

The average weekly volume growth across all stocks in the Tema Heart & Health ETF ETF was 106%. For the same stocks of the ETF, the average monthly volume growth was 114% and the average quarterly volume growth was -2%

Fundamental Analysis Ratings

The average fundamental analysis ratings, where 1 is best and 100 is worst, are as follows

Valuation Rating: 45
P/E Growth Rating: 66
Price Growth Rating: 49
SMR Rating: 68
Profit Risk Rating: 72
Seasonality Score: 28 (-100 ... +100)
View a ticker or compare two or three
HRTS
Daily Signal:
Gain/Loss:
Interact to see
Advertisement
A.I. Advisor
published General Information

General Information

Category Health

Profile
Details
Category
Health
Address
United Satets
Phone
N/A
Web
www.tema.co
HRTS saw its Stochastic Oscillator peaks and leaves the overbought zone